Establishment Labs (NASDAQ:ESTA) Shares Gap Up – What’s Next?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) gapped up before the market opened on Thursday . The stock had previously closed at $36.06, but opened at $38.00. Establishment Labs shares last traded at $38.09, with a volume of 113,380 shares.

Analyst Upgrades and Downgrades

Separately, Stephens reaffirmed an “overweight” rating and set a $52.00 target price on shares of Establishment Labs in a research note on Thursday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average target price of $57.40.

Establishment Labs Trading Up 0.8 %

The business’s 50 day simple moving average is $37.50 and its two-hundred day simple moving average is $41.35. The stock has a market cap of $1.20 billion, a P/E ratio of -16.62 and a beta of 1.12. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The business had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million. As a group, analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Several institutional investors have recently modified their holdings of the business. Brown Advisory Inc. grew its stake in shares of Establishment Labs by 23.1% in the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company’s stock worth $107,729,000 after purchasing an additional 438,057 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Establishment Labs by 29.3% in the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company’s stock worth $88,064,000 after purchasing an additional 433,484 shares during the last quarter. Findell Capital Management LLC grew its stake in shares of Establishment Labs by 28.5% in the fourth quarter. Findell Capital Management LLC now owns 1,346,480 shares of the company’s stock worth $62,032,000 after purchasing an additional 298,380 shares during the last quarter. William Blair Investment Management LLC boosted its position in Establishment Labs by 44.1% during the fourth quarter. William Blair Investment Management LLC now owns 812,825 shares of the company’s stock valued at $37,447,000 after acquiring an additional 248,888 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in Establishment Labs by 10.7% during the third quarter. Rice Hall James & Associates LLC now owns 793,300 shares of the company’s stock valued at $34,326,000 after acquiring an additional 76,959 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.